Last reviewed 2026-04-23 · How we verify

RCHOP21

Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells.

Rituximab targets and depletes CD20-positive B cells, while cyclophosphamide, doxorubicin, and prednisone work through various mechanisms to induce cell death in cancer cells. Used for Follicular lymphoma, Diffuse large B-cell lymphoma.

At a glance

Mechanism of action

Rituximab is a monoclonal antibody that binds to the CD20 antigen on B cells, leading to their depletion. Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death. Doxorubicin is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and inducing apoptosis. Prednisone is a corticosteroid that suppresses the immune system and inhibits inflammation.

Approved indications

• Follicular lymphoma
• Diffuse large B-cell lymphoma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Infection
• Fatigue

Key clinical trials

• Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma (NA)
• Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients (PHASE3)
• Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• RCHOP21 CI brief — competitive landscape report
• RCHOP21 updates RSS · CI watch RSS
• The Lymphoma Academic Research Organisation portfolio CI